TECHNOLOGY OVERVIEW
 

Vista Therapeutics is commercializing state-of-the-art nanotechnology develeped at Harvard University to produce lab-on-a-chip biosensors and integrated electronic signal detection systems for the simultaneous, real-time detection of multiple biomarkers in blood, urine, and wherever biologically relevant. Vista’s proprietary platform can facilitate measurement of transcripts and proteins from the same sample. The technology is based on nanowires, which can be assembled into nanowire chips, which can serve as biosensors for the label-free, multiplex detection of biomarkers.

Vista's disruptive nanotechnology platform will permit:

•   Simultaneous detection of proteins and gene transcripts.
•   Real-time assessment (like a cardiac monitor for blood/urine biomarkers of organ damage).
•   Label-free measurement.
•   Femtomolar sensitivity.
•   Integrated into package for point-of-care and at-home use.

Large Array of Biomarkers for Prediction or Assessment of Organ Damage facilitate:

•   Sets of biomarkers for all major types of organ damage and organ failure.
•   Biomarkers to identify adverse responders to drugs.
•   Biomarkers to identify at-risk groups for major diseases.
•   Markers for proteins, gene-transcripts and metabolites.
•   Markers for humans and animals.

Vista's technology is described in more detail on the other pages of the Technology section, but here is a summary of what it does:

•   Semi-conducting Nanowires are employed as FET sensors.
•   The sensors capture molecules covalently tethered to individual nanowires.
•   Capture molecules can be mAB’s, receptors, enzymes, peptides and oligonucleotides.
•   Target molecules reversibly bind to capture molecules without labelings.
•   Binding of target molecules hugely increases current thru NW circuits.
•   Result: Minute levels of multiple target molecules can be measured simultaneously & continuously with real-time read-out.

 

Nanowire Real-time Detection Signals